Lowering arterial pressure delays the oxidative stress generation in a renal experimental model of hypertension

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 4, 2009, Pages 348-354

  Polizio, Ariel H ^a   Gorzalczany, Susana B ^a   Tomaro, María L ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Angiotensin II; Antihypertensive drugs; Aorta; Arterial pressure; Oxidative stress

Indexed keywords

ANGIOTENSIN II; HEME OXYGENASE 1; LOSARTAN; MINOXIDIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERTENSION; MALE; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; THORACIC AORTA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HEME OXYGENASE (DECYCLIZING); HYPERTENSION, RENAL; LOSARTAN; MALE; MINOXIDIL; NADPH OXIDASE; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 74949098375     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181b76767     Document Type: Article

References (42)

1. Guyton JR, Dao DT, Lindsay KL, et al. Ultrastructure of hypertensive rat aorta. Hypertension. 1990;15:56-67.
2. Gironacci MM, Brosnihan KB, Ferrario CM, et al. Increased hypothalamic angiotensin-(1-7) levels in rats with aortic coarctation-induced hypertension. Peptides. 2007;28:1580-1585.
3. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension and cardiovascular disease: an update. Hypertension. 2001;37:1053-1059.
4. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension. What is the clinical significance? Hypertension. 2004;44:248-252.
5. Zafari AM, Ushio-Fukai M, Akers M, et al. Role of NADH/NADPH oxidase derived H2O2 in angiotensin II induced vascular hypertrophy. Hypertension. 1998;32:488-495.
6. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
7. Jalil JE, Perez A, OcaranzaMP, et al. Increased aortic NADPH oxidase activity in rats with genetically high angiotensin converting enzyme levels. Hypertension. 2005;46:1362-1367.
8. Rahman M, Kimura S, Nishiyama A, et al. Angiotensin II stimulates superoxide production via both angiotensin AT1A and AT1B receptors in mouse aorta and heart. Eur J Pharmacol. 2004;485:243-249.
9. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209.
10. Somers MJ, Mavromatis K, Galis ZS, et al. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000;101:1722-1728.
11. Maines MD, Traskhel GM, Kutty RK. Characterization of two constitutive forms of rat microsomal heme oxygenase: only one molecular species of the enzyme is inducible. J Biol Chem. 1986;261:411-419.
12. Maines MD. Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J. 1988;2:2557-2568.
13. Loboda A, Jazwa A, Grochot-Przeczek A, et al. Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2008;10:1767-1812.
14. Rojo-Ortega JM, Genest J. A method for production of experimental hypertension in rats. Can J Physiol Pharmacol. 1968;46:883-885.
15. Polizio AH, Gironacci MM, Tomaro ML, et al. Angiotensin-(1-7) blocks the angiotensin II-stimulated superoxide production. Pharmacol Res. 2007;56:86-90.
16. Anderson ME. Determination of glutathione and glutathione disulfide in biological samples. Method Enzymol. 1985;113:548-555.
17. Lowry HO, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin reagent. J Biol Chem. 1951;193:265-275.
18. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol. 2003;285:R277-R297.
19. Nistala R, Whaley-Connell A, Sowers JR. Redox Control of Renal Function and Hypertension. Antioxid Redox Signal. 2008;10:2047-2089.
20. Vasquez-Vivar J, Kalyanaraman B. Generation of superoxide from nitric oxide synthase. FEBS Lett. 2000;481:305-306.
21. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24:413-420.
22. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 2004;95:9220-9225.
23. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56: 387-437.
24. Wittwer J, Hersberger M. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids. 2007;77: 67-77.
25. Zangar RC, Davydov DR, Verma S. Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol Appl Pharmacol. 2004;199:316-331.
26. McCord JM, Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem. 1968;243:5753-5760.
27. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87-114.
28. Selemidis S, Sobey CG, Wingler K, et al. NADPH oxidases in the vasculature: molecular features, roles in disease, and pharmacological inhibition. Pharmacol Therapeut. 2008;120:254-291.
29. Landmesser U, Cai H, Dikalov S, et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin. Hypertension. 2002;40:511-515.
30. Li JM, Wheatcroft S, Fan LM, et al. Opposing roles of p47phox in basal versus angiotensin II stimulated alterations in vascular O2 - production, vascular tone, and mitogen-activated protein kinase activation. Circulation. 2004;109:1307-1313.
31. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovas Res. 2006;71:247-258.
32. Barton CH, Ni Z, Vaziri ND. Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int. 2001;60:1083-1087.
33. Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol. 1996;271: C1424-C1437.
34. Ungvari Z, Csiszar A, Kaminski PM, et al. Chronic high pressure-induced arterial oxidative stress: involvement of protein kinase C-dependent NAD(P)H oxidase and local renin-angiotensin system. Am J Pathol. 2004; 165:219-226.
35. Maeso R, Navarro-Cid J, Rodrigo E, et al. Effects of antihypertensive therapy on factors mediating endothelium-dependent relaxation in rats treated chronically with L-NAME. J Hypertens. 1999;17:221-227.
36. Nakata S, Tsutsui M, Shimokawa H, et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation. 2008;117:2211-2223.
37. Lehoux S, Tedgui A. Signal transduction of mechanical stresses in the vascular wall. Hypertension. 1998;32:338-345.
38. Kojda G, Hambrecht R. Molecular mechanisms of vascular adaptations to exercise. Physical activity as an effective antioxidant therapy. Cardiovasc Res. 2005;67:187-197.
39. Polizio AH, Balestrasse KB, Yannarelli GG, et al. Angiotensin II regulates cardiac hypertrophy via oxidative stress but not antioxidant enzyme activities in experimental renovascular hypertension. Hypertens Res. 2008;31:325-334.
40. Polizio AH, Balestrasse KB, Gornalusse GG, et al. Losartan exerts renoprotection through NAD(P)H oxidase downregulation in a renovascular model of hypertension. Regul Peptides. 2009;158:28-33.
41. Llesuy SF, Tomaro ML. Heme oxygenase and oxidative stress. Evidence of involvement of bilirubin as physiological protector against oxidative damage. Biochim Biophys Acta. 1994;1223:9-14.
42. Polizio AH, Gonzales S, Muñoz MC, et al. Behaviour of the anti-oxidant defense system and heme oxygenase-1 protein expression in fructosehypertensive rats. Clin Exp Pharmacol. 2006;33:734-739.